Patents Assigned to Charite Universitatsmedizin
-
Publication number: 20240159740Abstract: The invention relates to methods for assessing a level of T cell activation by one or more antigens or for assessing functional avidity of T cells for one or more antigens, the methods comprising providing a cell population comprising T cells, contacting said cell population with one or more antigens in vitro, and determining a level of a T-cell receptor (TCR) complex and/or component thereof in a sub-set of T cells of said cell population.Type: ApplicationFiled: March 18, 2022Publication date: May 16, 2024Applicant: Charité - Universitätsmedizin BerlinInventors: Andreas Thiel, Lucie Loyal, Larissa Henze, Julian Braun
-
Publication number: 20240092835Abstract: Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.Type: ApplicationFiled: June 7, 2023Publication date: March 21, 2024Applicants: Massachusetts Institute of Technology, Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut, Charité - Universitätsmedizin BerlinInventors: Michael Birnbaum, Brooke Huisman, Chiara Romagnani, Timo Rückert
-
Publication number: 20240066061Abstract: The invention provides a modified T cell, or an isolated population of immune cells expressing a CXCR3 isoform selected from CXCR3A, CXCR3B, and CXCR3alt, and optionally, further expressing transgenes comprising an artificial T cell receptor, and/or a CXCR3 ligand, for use as a medicament. The invention also provides the methods to obtain said cells, or populations of cells from a plurality of immune cells derived from a human subject. The invention also relates to assessment of CXCR3 splice variants and its ligands CXCL9, CXCL10, and CXCL11 in muscle-invasive bladder cancer (MIBC) patients, to enable patients to be stratified for their predicted response to a chemotherapy drug treatment, or clinical outcome.Type: ApplicationFiled: January 12, 2022Publication date: February 29, 2024Applicant: CHARITÉ-UNIVERSITÄTSMEDIZIN BERLINInventors: Hans Dieter VOLK, Michael SCHMÜCK-HENNERESSE, Tino VOLLMER, Petra REINKE, Stephan SCHLICKEISER
-
Publication number: 20240003835Abstract: The invention relates to a sample holder assembly (1) for microscopy comprising at least the following components: A first member (10) having a first opening (14) on a first side of the first member (10), and a circumferential wall portion (12) having an inward facing side (12-1) that faces toward the first volume (V1) and an outward facing side (12-2) opposite the inward facing side (12-1); A second member (20) having a first opening (24) at a first side of the second member (20), and a circumferential wall portion (22) having an inward facing side (22-1) facing toward the second volume (V2), wherein a shape of the outward facing side (12-2) of the wall portion (12) of the first member (10) is complementary to the inward facing side (22-1) of the wall portion (22) of the second member (20), such that the wall portion (12) of the first member (10) can be inserted in the second volume (V2), such that the first volume (V1) is at least partially comprised by the second volume (V2); A transparent membrane (30) haType: ApplicationFiled: October 6, 2021Publication date: January 4, 2024Applicant: CHARITÉ-UNIVERSITÄTSMEDIZIN BERLINInventors: Foo Wei TEN, Christian CONRAD, Roland EILS, Li-Ling YANG
-
Publication number: 20230357310Abstract: The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention.Type: ApplicationFiled: July 24, 2020Publication date: November 9, 2023Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Guy Hermans, Hendrik Fuchs
-
Patent number: 11802873Abstract: Provided herein is a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28? and CD8+CD57+CD28? in a sample obtained from a patient. Also provided herein is a system for predicting the probability of having or developing a non-fusion.Type: GrantFiled: May 29, 2018Date of Patent: October 31, 2023Assignee: CHARITÉ UNIVERSITÄTSMEDIZIN BERLINInventors: Simon Reinke, Sven Geissler, Georg Duda, Hans-Dieter Volk, Michael Fuchs, Katharina Schmidt-Bleek, Patrick Strube, Matthias Pumberger
-
Patent number: 11733029Abstract: The invention relates to a method and a computer program for estimating shape parameters of an image data set (1) of a fovea (100), comprising the steps of: Acquiring an image data set (1) of a macula (50), comprising a foveal pit (101) and a foveal rim (102) at least partially, Estimating the center of the foveal pit (101) from the image data set (1), Estimating from the center of the foveal pit (101), radially extending height profiles (c) of the fovea (100), For each height profile (c), fitting a model-function to the height profile (c), Estimating for each height profile (c) a set of fit parameters from the fitted model-function, Determining from the sets of estimated fit parameters at least one shape parameter of the fovea (100), particularly of the foveal pit (101). Determining at least one shape feature of at least a part of the fovea.Type: GrantFiled: July 19, 2018Date of Patent: August 22, 2023Assignee: CHARITÉ UNIVERSITÄTSMEDIZIN BERLINInventors: Alexander Brandt, Ella Maria Kadas, Sunil Yumar Yadav, Seyedamirhosein Motamedi, Paul Friedemann
-
Publication number: 20230183325Abstract: Subject matter of the present invention is a binder, e.g. protein or protein fragment, binding to complement-anaphylatoxin C5a and/or C3a and/or C4a and thereby inhibiting the activity of C5a and/or C3a and/or C4a for use in the treatment of a subject having an ocular wound and/or fibrosis.Type: ApplicationFiled: June 20, 2019Publication date: June 15, 2023Applicant: CHARITE - UNIVERSITATSMEDIZIN BERLINInventors: Tobias BROCKMANN, Eckart BERTELMANN, Uwe PLEYER
-
Patent number: 11639935Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.Type: GrantFiled: December 12, 2019Date of Patent: May 2, 2023Assignee: CHARITÉ UNIVERSITATSMEDIZIN BERLINInventors: Georg Duda, Hans-Dieter Volk, Simon Reinke, Christian Meisel, Christian Kleber, Sven Geissler, Katharina Schmidt-Bleek
-
Publication number: 20230065280Abstract: The invention concerns a medical device for at least periodical contact with diseased vessels such as a stent or a balloon catheter, for example, as well as a method for coating it with a defined solution. In accordance with the invention, a restenosis inhibitor is disposed on an outer surface in an active substance concentration of more than 4 ?g/mm2.Type: ApplicationFiled: January 20, 2021Publication date: March 2, 2023Applicants: INNORA GESELLSCHAFT MBH, CHARITÉ - UNIVERSITÄTSMEDIZIN BERLINInventors: Ole GEMEINHARDT, Sebastian SCHURMANN-KAUFELD
-
Publication number: 20230069794Abstract: A microscope system (100) configured to record images in at least a first and a second imaging mode (501, 502), comprising: An objective (1) collecting light (201) from a sample (11), An illumination module coupled to the objective, A first reimaging objective (5) generating an intermediate image of the sample and a second reimaging objective (6) that relays the intermediate image onto a detection module, An evaluation module (200) comprising a machine learning method (DL), trained with a first and a second set of images of the same sample, wherein the first and second set has been acquired in the first (501) and second imaging mode (502), respectively, wherein upon acquisition of an image (400) in the second imaging mode (502) the trained machine learning method (DL) outputs a restored image (401) that comprises fewer aberrations than the image (400) acquired in the second imaging mode (52, 53, 57).Type: ApplicationFiled: February 17, 2021Publication date: March 2, 2023Applicant: CHARITÉ-UNIVERSITÄTSMEDIZIN BERLINInventors: Yang LI-LING, Conrad CHRISTIAN, Ten FOO WEI, Eils ROLAND
-
Publication number: 20230033136Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.Type: ApplicationFiled: October 2, 2022Publication date: February 2, 2023Applicant: Charite Universitätsmedizin BerlinInventors: Georg DUDA, Hans-Dieter VOLK, Simon REINKE, Christian MEISEL, Christian KLEBER, Sven GEISSLER, Katharina SCHMIDT-BLEEK
-
Publication number: 20220339467Abstract: The invention relates to a device and a method for UV antisepsis, in particular for intracorporeal in vivo UV antisepsis on the human and animal body in the event of colonization with multiresistant pathogens (MRPs) such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The device comprises a light emitting diode chip, LED chip, configured to emit radiation in the UVC spectral range, wherein the LED chip forms a light emitting diode, LED, with a package; a spectral filter element set up to limit the radiation emitted by the LED chip substantially to wavelengths below 235 nm; and an optical element for directional emission of the radiation emitted by the LED.Type: ApplicationFiled: August 12, 2020Publication date: October 27, 2022Applicants: UNIVERSITÄTSMEDIZIN GREIFSWALD, CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, TECHNISCHE UNIVERSITÄT BERLIN, FERDINAND-BRAUN-INSTITUT GGMBH, LEIBNIZ-INSTITUT FÜR HÖCHSTFREQUENZTECHNIKInventors: Martina MEINKE, Jürgen LADEMANN, Axel KRAMER, Michael KNEISSL, Tim WERNICKE, Ulrike WINTERWERBER, Sven EINFELDT
-
Publication number: 20220313834Abstract: The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament.Type: ApplicationFiled: December 9, 2019Publication date: October 6, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Hendrik Fuchs
-
Publication number: 20220249674Abstract: The invention relates to an endosomal and/or lysosomal escape enhancing conjugate comprising a saponin optionally linked to a targeting molecule such as an antibody and optionally linked to an effector molecule such as a toxin or an oligonucleotide. The invention also relates to a therapeutic combination of such an endosomal and/or lysosomal escape enhancing conjugate of the invention and a functionalized binding molecule comprising an effector molecule, wherein the endosomal and/or lysosomal escape enhancing conjugate comprises an enhancer of said effector molecule, i.e. a saponin. In particular the invention relates to such a therapeutic combination for use as a medicament, in particular for use in the treatment of a tumour.Type: ApplicationFiled: July 27, 2020Publication date: August 11, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Hendrik Fuchs, Ruben Postel
-
Publication number: 20220218837Abstract: The invention relates to antibody-drug conjugates (ADC) that are potentiated by co-administration of the ADC with a moiety comprising covalently linked saponin. The invention also relates to antibody-oligonucleotide conjugates (AOC) that are potentiated by co-administration of the AOC with a moiety comprising covalently linked saponin. The invention also relates to ADCs and AOCs which are conjugated with a saponin via a covalent linker. The invention further relates to an effector moiety such as a toxin or an antisense oligonucleotide such as for example a BNA, conjugated with a saponin via a covalent linkage. The invention also relates to a BNA covalently conjugated with a targeting moiety such as an antibody.Type: ApplicationFiled: December 9, 2019Publication date: July 14, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Hendrik Fuchs
-
Publication number: 20220186315Abstract: The invention relates to an in vitro method for determining the severity or a grade of a human papillomavirus (HPV)-induced dysplasia or whether cervical carcinoma is present, and related materials, devices and computer-implementation of the method. The present invention comprises quantitatively determining an expression level of (i) viral and (ii) cellular messenger RNA (mRNA) in a sample obtained from the subject, wherein the determined viral mRNA encodes an HPV oncoprotein E6 and/or E7, and wherein the determined cellular mRNA comprises mRNA of at least one cellular proliferation marker, of at least one cancer stem cell marker, and of at least one tumor marker, and deducing from the quantity of said viral mRNA and said cellular mRNA the severity or a grade of the dysplasia or whether cervical carcinoma is present in the subject.Type: ApplicationFiled: February 7, 2020Publication date: June 16, 2022Applicant: Charité - Universitätsmedizin BerlinInventor: Andreas Kaufmann
-
Publication number: 20220111066Abstract: The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention.Type: ApplicationFiled: December 9, 2019Publication date: April 14, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Hendrik Fuchs
-
Publication number: 20220072149Abstract: The invention relates to a molecular scaffold suitable for covalently binding at least one biologically active molecule to a carrier molecule, the scaffold comprising a polymeric structure and the biologically active molecules covalently bound to said polymeric structure, and wherein the scaffold further comprises a chemical group for covalently coupling of the scaffold to the carrier molecule. The biologically active molecule has a molecular weight of 3.000 Dalton or less, such as 1.700 Dalton-1.950 Dalton. The biologically active molecule is an amphiphilic molecule in some embodiments. The biologically active molecule is a single specific molecule or is a mixture of different types of molecules, when more than one biologically active molecules are covalently bound to the polymeric (or oligomeric) structure. In particular, the invention relates to monoclonal antibody-based antibody-drug conjugates with improved therapeutic window of the drug due to covalent linkage of (a cluster of) potentiator molecules, e.Type: ApplicationFiled: December 9, 2019Publication date: March 10, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Hendrik Fuchs
-
Publication number: 20220054643Abstract: The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention.Type: ApplicationFiled: December 9, 2019Publication date: February 24, 2022Applicants: Sapreme Technologies B.V., Charité - Universitätsmedizin BerlinInventors: Ruben Postel, Hendrik Fuchs